raw materials – Page 6

Regulatory query on nitrosamines during regulatory inspection – preventing product recall

Effective Management of Nitrosamines During Regulatory Inspections to Prevent Product Recalls The emergence of nitrosamines as a critical regulatory focus has raised alarms within pharmaceutical manufacturing, particularly during inspections. The…

Expired material used during inspection walkthrough – GMP storage compliance requirements

Investigating the Use of Expired Materials During Inspection Walkthroughs Pharmaceutical organizations must adhere to stringent regulations regarding material storage and shelf-life management. Recent observations have raised concerns about the potential…

Risk mitigation plan inadequate during risk assessment – CAPA for nitrosamine findings

Addressing Inadequate Risk Mitigation Plans During Nitrosamine Risk Assessments The pharmaceutical industry faces an ongoing challenge with nitrosamine impurities found in raw materials, which can jeopardize product integrity and patient…

Improper segregation of materials during inventory reconciliation – inspection defense documentation

Material Mismanagement during Inventory Reconciliation: A Detailed Investigation Protocol In the realm of pharmaceutical manufacturing, maintaining rigorous control over raw materials is crucial for ensuring product quality and compliance with…

Potential nitrosamine source identified during risk assessment – risk mitigation and control strategy

Identifying Risks of Nitrosamines in Raw Materials: A Comprehensive Playbook In the evolving landscape of pharmaceutical manufacturing, the presence of nitrosamines poses substantial concerns. As regulatory bodies like the FDA…

FIFO not followed during deviation investigation – preventing repeat storage deviations

Investigating Non-Adherence to FIFO Practices: Addressing Storage Deviations in Pharma In pharmaceutical manufacturing, adherence to the First-In-First-Out (FIFO) principle is critical for effective inventory management and ensuring product integrity. A…

Nitrosamine risk assessment incomplete during ongoing surveillance – FDA/EMA nitrosamine expectations

Addressing Incomplete Nitrosamine Risk Assessments During Ongoing Surveillance The pharmaceutical industry continues to grapple with the challenges posed by nitrosamines, particularly in the context of ongoing surveillance. Regulatory bodies like…

FIFO not followed during routine checks – GMP storage compliance requirements

Failure to Adhere to FIFO in Routine Checks: A Comprehensive Investigation Approach In the complex environment of pharmaceutical manufacturing, the adherence to Good Manufacturing Practices (GMP) is paramount. One critical…

Nitrosamine risk assessment incomplete during risk assessment – preventing product recall

How to Address Incomplete Nitrosamine Risk Assessments to Prevent Product Recalls In recent years, the pharmaceutical industry has faced significant scrutiny concerning the presence of nitrosamines in drug products, stemming…

FIFO not followed during inspection walkthrough – GMP storage compliance requirements

Investigation of FIFO Compliance during Inspection Walkthroughs in GMP Storage In pharmaceutical manufacturing, adherence to Good Manufacturing Practices (GMP) is critical for maintaining product quality and ensuring patient safety. A…

Risk mitigation plan inadequate during ongoing surveillance – inspection-ready justification

Addressing Inadequate Risk Mitigation Plans During Surveillance: A Comprehensive Playbook In the evolving landscape of pharmaceutical manufacturing, the risks associated with raw materials—especially concerning nitrosamines—are pressing. A recent uptick in…

Environmental monitoring gaps during inspection walkthrough – product quality impact assessment

Assessing the Impact of Environmental Monitoring Gaps During Inspections on Product Quality During routine inspections in pharmaceutical manufacturing facilities, environmental monitoring gaps can significantly impact product quality and safety. When…